Preparation and Characterization of Self-Microemusifying Drug Delivery System (Smedds) of Cisplatin for Oral Use in Ovarian Cancer Treatment

Abstract

Cancer is one of the most leading causes of death in the world. Ovarian cancer is the seventh most common cancer in women. Also, it has the highest, mortality rate among female reproductive system cancers (1). According to the American Cancer Society in 2018, 22240 new cases of ovarian cancer will be diagnosed and 14070 women will die of ovarian cancer in the United States (2). The highest incidences are related in Europe, Canada and the United States. The lowest incidences are reported in China and Africa. According to GLOBOCAN 2008 database, the incidence rates are reported as over 11 cases per 100000 in Europe, less than 3 cases per 100000 in Africa and 4-8 cases per 100000 in South American, Asian and Caribbean countries (3). The latest cancer mortality statistics of the World Health Organization (WHO) showed that mortality will increase by approximately 45% until 2030 (4). Ovarian cancer has different risk factors like family history, age, early age menarche, menopause, parity, oral contraceptive use, lactation, obesity, cigarette smoking and alcohol consumption (5-7). Epithelial ovarian cancer is the most common type of ovarian cancer. Early diagnosis increases the chances successful treatment. The pathogenesis of ovarian cancer hasnít been elucidated yet, but ovulation, hormonal factors and inflammations have an important role in it (8, 9). There are two types of ovarian tumors. Type I tumors tend to be less aggressive and slow-growing like low grade malign serous tumors, low grade malign endometrioid carcinoma and mucinous carcinoma. Type II tumors are more aggressive than Type I tumors. They are high grade malign serous carcinoma, carcinosarcoma and undifferentiated carcinoma (10, 11). Ovarian cancer is staged by using the FIGO staging system which has 4 stages. A tumor is limited to the ovary at stage I. During stage II, tumor involves one or both of the ovaries. Pelvic extension and primary peritoneal tumor occurred. At stage III,

Antibacterial activity and cytocompatibility evaluation of cefpodoxime proxetil loaded eudragit rs 100 nanoparticles

“…In vitro release pattern of CFP and nanoparticles was studied over 24 hours using a dialysis method [57]. 2 mg CFP and nanoparticles carrying an equivalent amount of CFP were placed in a cellulose acetate dialysis bag (molecular weight cut-off 12-14 kDa, Sigma Aldrich, USA) with 1 mL distilled water separately and locked by special clamps.…”

F127/Cisplatin Microemulsions: In Vitro, In Vivo and Computational Studies

“…Recently, the reverse microemulsion method was employed to synthesize the Cis nanoparticles, later coated with lipids that improved the anti-cancer effect of Cis [20]. A self-microemulsion drug delivery system incorporating Cis has also been studied recently [21]. Similarly, lipid-based nanosystems of Cis have been developed in the past to improve anti-tumor activity [22,23].…”